المؤلفون: de la Rubia, Javier, González, Bernardo, Cruz-Jentoft, Alfonso J., Iglesias, Lorena, Pérez Persona, Ernesto, Gironella Mesa, Mercedes, Jarque, Isidro

المساهمون: Institut Català de la Salut, de la Rubia J, Jarque I Hematology Department, H.U. i Politècnic La Fe. Valencia, Spain. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III. Madrid, Spain. González B Hematology Department, H.U. de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. Cruz-Jentoft AJ Geriatric Unit, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. Iglesias L Hematology Department, C.H.U. A Coruña. A Coruña, Spain. Persona EP Hematology Department H. U, Vitoria-Gasteiz, Álava, Spain. Gironella M Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Persones grans, Sang - Malalties - Diagnòstic, Medicaments - Toxicologia, DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Geriatric Assessment, PUBLIC HEALTH::Environmental Health::Science::Toxicology::Toxicity, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::evaluación geriátrica, SALUD PÚBLICA::salud ambiental::ciencia::toxicología::toxicidad

الوصف: Chemotherapy; Geriatric assessment; Toxicity ; Quimioterapia; Evaluación geriátrica; Toxicidad ; Quimioteràpia; Avaluació geriàtrica; Toxicitat ; Introduction The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weighted receiver operating characteristic (ROC) analysis and quantified by the area under the curve (AUC). Material and Methods The RETROGAH was a retrospective cohort study including 126 patients who had previously participated in the GAH study. Patients were ≥ 65 years old with newly diagnosed myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), multiple myeloma (MM), or chronic lymphoid leukemia (CLL) and treated with standard front-line therapy within three months after having completed the GAH scale. Results The optimal cut-off value of the GAH total score to discriminate patients at higher risk of treatment toxicity was 42, with 68.5% sensitivity and 55.8% specificity. Using this value, 66.1% of patients evaluated were found to develop some type of toxicity. The AUC was 0.6259 (95% CI: 0.512–0.739; p = 0.035). Discussion The GAH scale not only would enable clinicians to individualize therapy based on individual risk of toxicity but also discriminate patients that will benefit most from intensive treatments from those requiring an adapted approach. While futures studies in clinical practice may improve the model and overcome its limitations, the GAH scale should not be used alone when making treatment decisions. ; This study was supported by Celgene España S.L.

وصف الملف: application/pdf

العلاقة: Journal of Geriatric Oncology;14(1); https://doi.org/10.1016/j.jgo.2022.10.016Test; de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, et al. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study. J Geriatr Oncol. 2023 Jan;14(1):101401.; https://hdl.handle.net/11351/9326Test; 000946209600001

الإتاحة: https://doi.org/10.1016/j.jgo.2022.10.016Test
https://hdl.handle.net/11351/9326Test

المؤلفون: Robles Alonso, Virginia, Martínez Valle, Fernando, Borruel Sainz, Natalia

المساهمون: Institut Català de la Salut, Robles-Alonso V Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Martínez-Valle F Unitat de Malalties Autoimmunes, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Borruel N Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Immunoteràpia - Efectes secundaris, Malalties autoimmunitàries - Tractament, Medicaments - Toxicologia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy, Other subheadings::Other subheadings::Other subheadings::/adverse effects, DISEASES::Immune System Diseases::Autoimmune Diseases, CHEMICALS AND DRUGS::Biological Factors, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos

الوصف: Adverse drugs reaction; Immune check-point inhibitors therapy; Immunosuppression therapy ; Reacción adversa a medicamentos; Terapia con inhibidores del punto de control inmunitario; Terapia inmunosupresora ; Reaccions adverses als fàrmacs; Teràpia amb inhibidors del punt de control immune; Teràpia d'immunosupressió ; In recent years, immunotherapy has become an important pillar of cancer treatment, with high response rates regardless of tumor histology or baseline mutations, sometime in patients without any alternative of treatment. Moreover, these treatments are moving from later line therapies to front-line therapies in the metastasic setting. However, immune activation associated with immune check-point inhibitors (ICI) is not selective and a large variety of immune-related adverse events, with an increasing frequency, have been associated with anti-PD1, anti-PD-1/L-1 and anti-CTLA-4 agents. In clinical trials, and sometimes also in real life practice, patients who develop severe toxicities on ICI-based therapies are usually not allowed to resume ICI once their disease progresses, because of the chance of developing severe irAEs on rechallenge with immunotherapies. Moreover, patients with irAEs suffer important side effects due to the high dose corticosteroids that are used to treat them. Therapy with ICI is sometimes the only alternative for certain patients, and for this reason co treatment with classic (DMARDS) or biologic immunosuppression therapy and ICI must be considered. Co-treatment with this type of immunosuppressant drugs, apart from allowing the maintenance of ICI therapy, drive to a lesser use of corticosteroids, with an improvement of the safety and quality of life of the patients. Such a tailored scheme of treatment is mostly an expert opinion based on recommendation and currently there is scarce evidence supporting it. Herein we present comprehensive, current recommendations and real-world data on the use of co-treatment with ICI and DMARDS and biologic immunosuppression.

وصف الملف: application/pdf

العلاقة: Frontiers in Medicine;9; https://doi.org/10.3389/fmed.2022.906098Test; Robles-Alonso V, Martínez-Valle F, Borruel N. Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management. Front Med. 2022 Jun 30;9:90698.; https://hdl.handle.net/11351/8213Test; 000826727200001

الإتاحة: https://doi.org/10.3389/fmed.2022.906098Test
https://hdl.handle.net/11351/8213Test

المؤلفون: Servei Català de la Salut. Gerència del Medicament

المساهمون: Departament de Salut

المصدر: Scientia

مصطلحات موضوعية: Medicaments - Toxicologia, Medicaments - Prescripció, Persones grans - Ús dels medicaments, HEALTH CARE::Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Potentially Inappropriate Medication List, NAMED GROUPS::Persons::Age Groups::Adult::Aged, ATENCIÓN DE SALUD::administración de los servicios de salud::calidad de la atención sanitaria::garantía de calidad de la atención sanitaria::Lista de medicamentos potencialmente inadecuados, DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::adulto::anciano

الوصف: Fàrmacs inapropiats; Persones d'edat avançada; Seguretat clínica ; Fármacos inapropiados; Personas de edad avanzada; Seguridad clínica ; Inappropriate drugs; Elderly people; Clinical safety ; Aquest document recull la llista de medicaments potencialment inapropiats per a persones d’edat avançada independentment de la seva condició clínica i diagnòstic que es va elaborar l’any 2019. Cada any es revisa si cal fer-ne alguna modificació. ; Este documento recoge la lista de medicamentos potencialmente inapropiados para personas de edad avanzada independientemente de su condición clínica y diagnóstico que se elaboró en 2019. ; This document lists potentially inappropriate drugs for the elderly regardless of their clinical condition and diagnosis that was compiled in 2019.

وصف الملف: application/pdf

العلاقة: Servei Català de la Salut. Gerència del Medicament. Fàrmacs potencialment inapropiats per a persones d’edat avançada. Barcelona: Servei Català de la Salut; 2021.; https://hdl.handle.net/11351/5814Test

الإتاحة: https://hdl.handle.net/11351/5814Test

المؤلفون: Javier de la Rubia, Bernardo González, Alfonso J. Cruz-Jentoft, Lorena Iglesias, Isidro Jarque, Ernesto Pérez Persona, Rafael Lluch, Carmen Marrero, Maite Zudaire, Mercedes Gironella, José Ángel Hernández-Rivas, Montserrat Arnan, Carmen Olivier, Cristina Encinas, Juan Alfonso Soler, Ángel Ramírez Payer, Alfonso Casado, Patricia Fernández, David Vilanova, Santiago Bonanad

المساهمون: Institut Català de la Salut, [de la Rubia J, Jarque I] Hematology Department, H.U. i Politècnic La Fe. Valencia, Spain. School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III. Madrid, Spain. [González B] Hematology Department, H.U. de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. [Cruz-Jentoft AJ] Geriatric Unit, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain. [Iglesias L] Hematology Department, C.H.U. A Coruña. A Coruña, Spain. [Persona EP] Hematology Department H. U, Vitoria-Gasteiz, Álava, Spain. [Gironella M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Sang - Malalties - Diagnòstic, Oncology, Medicaments - Toxicologia, Environmental Health::Science::Toxicology::Toxicity [PUBLIC HEALTH], Geriatrics and Gerontology, Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES], neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES], Investigative Techniques::Epidemiologic Methods::Data Collection::Geriatric Assessment [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Persones grans, técnicas de investigación::métodos epidemiológicos::recopilación de datos::evaluación geriátrica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], salud ambiental::ciencia::toxicología::toxicidad [SALUD PÚBLICA]

الوصف: Chemotherapy; Geriatric assessment; Toxicity Quimioterapia; Evaluación geriátrica; Toxicidad Quimioteràpia; Avaluació geriàtrica; Toxicitat Introduction The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weighted receiver operating characteristic (ROC) analysis and quantified by the area under the curve (AUC). Material and Methods The RETROGAH was a retrospective cohort study including 126 patients who had previously participated in the GAH study. Patients were ≥ 65 years old with newly diagnosed myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), multiple myeloma (MM), or chronic lymphoid leukemia (CLL) and treated with standard front-line therapy within three months after having completed the GAH scale. Results The optimal cut-off value of the GAH total score to discriminate patients at higher risk of treatment toxicity was 42, with 68.5% sensitivity and 55.8% specificity. Using this value, 66.1% of patients evaluated were found to develop some type of toxicity. The AUC was 0.6259 (95% CI: 0.512–0.739; p = 0.035). Discussion The GAH scale not only would enable clinicians to individualize therapy based on individual risk of toxicity but also discriminate patients that will benefit most from intensive treatments from those requiring an adapted approach. While futures studies in clinical practice may improve the model and overcome its limitations, the GAH scale should not be used alone when making treatment decisions. This study was supported by Celgene España S.L.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::891146866b1eb2024f31a99454aa2826Test
https://hdl.handle.net/11351/9326Test

المؤلفون: Virginia Robles-Alonso, Fernando Martínez-Valle, Natalia Borruel

المساهمون: Institut Català de la Salut, [Robles-Alonso V] Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Martínez-Valle F] Unitat de Malalties Autoimmunes, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Borruel N] Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Malalties autoimmunitàries - Tractament, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], factores biológicos [COMPUESTOS QUÍMICOS Y DROGAS], terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Other subheadings::Other subheadings::/adverse effects [Other subheadings], Immune System Diseases::Autoimmune Diseases [DISEASES], enfermedades del sistema inmune::enfermedades autoinmunes [ENFERMEDADES], Immunoteràpia - Efectes secundaris, Medicaments - Toxicologia, General Medicine, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Biological Factors [CHEMICALS AND DRUGS]

الوصف: Adverse drugs reaction; Immune check-point inhibitors therapy; Immunosuppression therapy Reacción adversa a medicamentos; Terapia con inhibidores del punto de control inmunitario; Terapia inmunosupresora Reaccions adverses als fàrmacs; Teràpia amb inhibidors del punt de control immune; Teràpia d'immunosupressió In recent years, immunotherapy has become an important pillar of cancer treatment, with high response rates regardless of tumor histology or baseline mutations, sometime in patients without any alternative of treatment. Moreover, these treatments are moving from later line therapies to front-line therapies in the metastasic setting. However, immune activation associated with immune check-point inhibitors (ICI) is not selective and a large variety of immune-related adverse events, with an increasing frequency, have been associated with anti-PD1, anti-PD-1/L-1 and anti-CTLA-4 agents. In clinical trials, and sometimes also in real life practice, patients who develop severe toxicities on ICI-based therapies are usually not allowed to resume ICI once their disease progresses, because of the chance of developing severe irAEs on rechallenge with immunotherapies. Moreover, patients with irAEs suffer important side effects due to the high dose corticosteroids that are used to treat them. Therapy with ICI is sometimes the only alternative for certain patients, and for this reason co treatment with classic (DMARDS) or biologic immunosuppression therapy and ICI must be considered. Co-treatment with this type of immunosuppressant drugs, apart from allowing the maintenance of ICI therapy, drive to a lesser use of corticosteroids, with an improvement of the safety and quality of life of the patients. Such a tailored scheme of treatment is mostly an expert opinion based on recommendation and currently there is scarce evidence supporting it. Herein we present comprehensive, current recommendations and real-world data on the use of co-treatment with ICI and DMARDS and biologic immunosuppression.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f75863350a0693558fa35fb343b9ba0Test
https://doi.org/10.3389/fmed.2022.906098Test

المؤلفون: Sheila, Bermejo, Mónica, Bolufer, Mar, Riveiro-Barciela, Maria José, Soler

المساهمون: Institut Català de la Salut, [Bermejo S, Bolufer M, Soler MJ] Servei de Nefrologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Centro de Referencia en Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), Barcelona, Spain. [Riveiro-Barciela M] Unitat Hepàtica, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Nefrotoxicologia, Other subheadings::Other subheadings::/chemically induced [Other subheadings], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological [CHEMICALS AND DRUGS], Immunotoxicologia, Other subheadings::Other subheadings::/adverse effects [Other subheadings], enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::nefritis::nefritis intersticial [ENFERMEDADES], Otros calificadores::Otros calificadores::/inducido químicamente [Otros calificadores], Medicaments - Toxicologia, Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Nephritis::Nephritis, Interstitial [DISEASES], General Medicine, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica [COMPUESTOS QUÍMICOS Y DROGAS]

الوصف: Chronic kidney disease; Dialysis; Immunotherapy Enfermedad renal cronica; Diálisis; Inmunoterapia Malaltia renal crònica; Diàlisi; Immunoteràpia The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases. This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a04a06d6c4d004da794a5387cef599bTest
https://hdl.handle.net/11351/8175Test

المساهمون: Barrena Gómez, Raquel

مصطلحات موضوعية: Medicaments Toxicologia, Aigües residuals Anàlisi

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od_______272::5ecc43fad8ac9f42704601ba07eb833cTest
https://hdl.handle.net/2072/419950Test

المؤلفون: Rodríguez Rey, Mauro, Vicent i Huguet, Teresa, Universitat Autònoma de Barcelona. Facultat de Ciències

المساهمون: Barrena Gómez, Raquel

المصدر: Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname

مصطلحات موضوعية: Medicaments Toxicologia, Aigües residuals Anàlisi

الوصف: En el present estudi s'ha fet un seguiment baromètric de la producció de biogàs de tres compostos farmacèutics mitjançant tests de degradació anaeròbia. El llot del digestor anaerobi de l'estació depuradora d'aigües residuals (EDAR) de Granollers s'ha emprat com a inòcul. En un primer experiment, s'ha fet l'estudi de l'etapa metanogènica, amb metanol com a substrat i les concentracions de 5, 10 i 20 mg·L-1 d'àcid clofíbric (CLOFI, regulador lípid), ibuprofè (IBU, anti-inflamatori) i carbamazepina (CARBA, antiepilèptic/analgèsic). En un segon experiment, s'ha estudiat l'etapa acetogènica, amb àcid propiònic com a substrat i amb concentracions de 20 i 100 mg·L-1 dels mateixos fàrmacs. Per una banda, en el primer experiment, no s'ha observat degradació dels fàrmacs i cap d'ells presenta toxicitat pel llot anaerobi. CARBA i IBU s'adsorbeixen majoritàriament a la fase sòlida. Per altra banda, en l'etapa acetogènica ni CARBA ni IBU s'han degradat i tampoc presenten toxicitat en cap de les concentracions provades. Com en el cas anterior, la majoria d'aquests fàrmacs queda adsorbit en el llot. En canvi, CLOFI es degrada en 100 mg·L-1 de concentració donant com a producte intermedi un metabòlit. En el presente estudio se ha hecho un seguimiento barométrico de la producción de biogás de tres compuestos farmacéuticos mediante test de degradación anaerobia. El lodo del digestor anaerobio de la estación depuradora de aguas residuales (EDAR) de Granollers se ha utilizado como inóculo. En un primer experimento, se ha hecho el estudio de la etapa metanogènica, con metanol como sustrato y las concentraciones de 5, 10 y 20 mg·L-1 de ácido clofíbrico (CLOFI, regulador lípido), ibuprofeno (IBU, anti-inflamatorio) y carbamazepina (CARBA, antiepiléptico/analgésico). En un segundo experimento, se ha estudiado la etapa acetogénica, con ácido propiónico como sustrato y con concentraciones de 20 y 100 mg·L-1 de los mismos fármacos. Por un lado, en el primer experimento, no se ha observado degradación de los fármacos y ninguno de ellos presenta toxicidad para el lodo anaerobio. CARBA e IBU se adsorben mayoritariamente en la fase sólida. Por otro lado, en la etapa acetogénica ni CARBA ni IBU se han degradado y tampoco presentan toxicidad en ninguna de las concentraciones probadas. Como en el caso anterior, la mayoría de estos fármacos queda adsorbida en el lodo. En cambio, CLOFI , se degrada en 100 mg·L-1 de concentración dando como producto intermedio un metabolito. During the present work the biogas production has been monitored from three pharmaceutical compounds by anaerobic degradation test. Anaerobic digester sludge of the wastewater treatment plant (WWTP) of Granollers was used as inoculum. In the first experiment, the methanogenic phase has been studied using methanol as substrate and 5, 10 and 20 mg·L-1 of clofibric acid (CLOFI, lipid regulator), ibuprofen (IBU, anti-inflammatory) and carbamazepine (CARBA, antiepileptic/analgesic). In the second experiment acetogenic phase has been studied using propiònic acid as substrate and 20 and 100 mg·L-1 of the same drugs. In one hand, in the first experiment, there was no degradation of added drugs observed and none of them were toxic for anaerobic sludge. CARBA and IBU were mostly adsorbed in solid phase. In the other hand, in the acetogenic phase, CARBA and IBU have not been degraded and do not show toxicity at al tested concentrations. As in the previous case, most of these drugs are adsorbed on the sludge. CLOFI is degraded in 100 mg·L-1 given as an intermediate product as a metabolite.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5ecc43fad8ac9f42704601ba07eb833cTest
http://hdl.handle.net/2072/419950Test

المؤلفون: Azemà Rovira, Maria

المساهمون: Universitat de Girona. Facultat de Medicina, Rodríguez Gómez, Carmen María, Puig i Miquel, Teresa

المصدر: Medicina (TFG)
DUGiDocs – Universitat de Girona
instname

مصطلحات موضوعية: Lungs -- Cancer -- Treatment, Pulmons -- Càncer -- Cirurgia, Medicaments -- Toxicologia, Lungs -- Cancer -- Immunotheraphy, Pulmons -- Càncer -- Immunoteràpia, Drugs -- Toxicology, Pulmons -- Càncer -- Tractament, Lungs -- Cancer -- Surgery

الوصف: Background: Lung cancer is one of the leading causes of death in the world. Thanks to scientific progress, immunotherapy has now begun to be studied as a neoadjuvant treatment for patients with advanced-stage non-small cell lung cancer. Nowadays, it is being seen that immunotherapy will be the future treatment for this type of patient. That is why it will be necessary to know what side effects are produced by the treatment of IT (Immunotherapy) as the only therapy, in those patients who are candidates to receive a surgical rescue after the neoadjuvant treatment and therefore be able to know what we will face. So far, it is important to know the immunotherapy in all its possible aspects, if we manage to know all the side effects produced and all the possible post-surgery comorbidities, we will have the necessary information to develop the appropriate tools to prevent everything that can negatively influence the subsequent surgical rescue of these patients. Objective: The main objective of this study is to establish which side effects produced by neoadjuvant immunotherapy have an influence on the surgical rescue of patients with stage N2 (nodal extent) non-small cell lung carcinoma regardless of their T (tumor extent). Design: A prospective multicenter cohort will be conducted. Patients with a lung carcinoma (adenocarcinoma or squamous cell carcinoma) with an N2 extension regardless of the size of their T and M0 (distant metastasis), according to the TNM classification, will be introduced in this study to be carried out in the following university hospitals: Dr. Josep Trueta Hospital, Bellvitge Hospital of Barcelona and Vall d’Hebron Hospital. Outcomes: Our variable of interest, is the occurrence of toxicity due to treatment with neoadjuvant immunotherapy, of patients with a potentially resectable lung carcinoma. It will be analyzed as a nominal dichotomous qualitative variable

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9ed3befd3d335e46086ee8b5dad18365Test
http://hdl.handle.net/10256/19836Test

المؤلفون: N Carballo, Javier Martínez-Casanova, Sonia Luque, Santiago Grau, Luisa Sorlí

المصدر: Infection and Drug Resistance

مصطلحات موضوعية: 0301 basic medicine, Fetge -- Medicaments -- Toxicologia, medicine.medical_specialty, Posaconazole, hepatotoxicity, Combination therapy, therapeutic drug monitoring, 030106 microbiology, Aspergillosis, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, Therapeutic index, Internal medicine, medicine, case report, Pharmacology (medical), Pharmacology, Voriconazole, chemistry.chemical_classification, medicine.diagnostic_test, business.industry, medicine.disease, Infectious Diseases, chemistry, Therapeutic drug monitoring, Azole, antifungal agents, Caspofungin, business, medicine.drug

الوصف: Azole antifungals have frequently been linked to the presence of hepatotoxicity, but there is scarce information on cross-toxicity between these drugs or on the possibility of using some of them when this type of toxicity occurs. We report the case of a 64-year-old man with invasive aspergillosis (IA) leading to spondylodiscitis with neurological involvement. Early management included intravenous (iv) voriconazole, which had to be interrupted after 1 week due to liver damage. Therapeutic drug monitoring (TDM) of voriconazole showed that the plasma concentration was within the therapeutic range. However, it was replaced by a combination therapy of oral posaconazole plus iv caspofungin. Posaconazole allowed normalization of liver enzymes. After finishing posaconazole monotherapy on an outpatient basis, the patient made a full recovery. This case report provides further evidence that oral posaconazole is safe and effective as rescue therapy after the appearance of voriconazole-induced liver toxicity.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e132c624c4b216bab066e3ef7dbfafTest
http://europepmc.org/articles/PMC5844257Test